EA201100078A1 - Производные пиримидина в качестве ингибиторов киназы - Google Patents

Производные пиримидина в качестве ингибиторов киназы

Info

Publication number
EA201100078A1
EA201100078A1 EA201100078A EA201100078A EA201100078A1 EA 201100078 A1 EA201100078 A1 EA 201100078A1 EA 201100078 A EA201100078 A EA 201100078A EA 201100078 A EA201100078 A EA 201100078A EA 201100078 A1 EA201100078 A1 EA 201100078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
pyrimidine
kinase inhibitors
pyrimidine derivatives
igf
Prior art date
Application number
EA201100078A
Other languages
English (en)
Inventor
Томас Х Марсилье, III
Вэньшу Лу
Бэй Чэнь
Сяосюй Хэ
Сончунь Цзян
Куньйон Ян
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201100078A1 publication Critical patent/EA201100078A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны новые производные пиримидина и содержащие их фармацевтические композиции и способы применения таких соединений. Например, производные пиримидина, предлагаемые в настоящем изобретении, можно применять для лечения, облегчения протекания или предупреждения патологического состояния, которое реагирует на ингибирование инсулиноподобного фактора роста (IGF-1R) или киназы анапластической лимфомы (ALK).
EA201100078A 2008-06-25 2009-06-24 Производные пиримидина в качестве ингибиторов киназы EA201100078A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
PCT/US2009/048509 WO2009158431A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201100078A1 true EA201100078A1 (ru) 2011-08-30

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100078A EA201100078A1 (ru) 2008-06-25 2009-06-24 Производные пиримидина в качестве ингибиторов киназы

Country Status (11)

Country Link
EP (1) EP2331526A2 (ru)
JP (1) JP2011526291A (ru)
KR (1) KR20110020940A (ru)
CN (1) CN102203083A (ru)
AU (1) AU2009262198B2 (ru)
BR (1) BRPI0914545A2 (ru)
CA (1) CA2729546A1 (ru)
EA (1) EA201100078A1 (ru)
MX (1) MX2010014568A (ru)
UA (1) UA101057C2 (ru)
WO (1) WO2009158431A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2785709B1 (en) * 2011-11-29 2017-05-10 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Alk 키나아제 억제제
BR112015022993B1 (pt) * 2013-03-14 2021-12-14 Sumitomo Dainippon Pharma Oncology, Inc. Inibidores de jak2 e alk2, composição farmacêutica compreendendo os referidos inibidores e uso destes
KR101881886B1 (ko) * 2014-05-30 2018-07-25 베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니 Alk 키나제 억제제, 이의 제조방법 및 이의 용도
US10377743B2 (en) * 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN107488148A (zh) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 一种苯丙酰胺类杀虫剂及其制备方法
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US8178671B2 (en) * 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
JP4741491B2 (ja) * 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ, インコーポレイテッド 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CA2538413A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP3012249A1 (en) * 2006-12-08 2016-04-27 Novartis AG Compounds and composition as protein kinase inhibitors
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂

Also Published As

Publication number Publication date
KR20110020940A (ko) 2011-03-03
WO2009158431A3 (en) 2010-03-11
CA2729546A1 (en) 2009-12-30
JP2011526291A (ja) 2011-10-06
EP2331526A2 (en) 2011-06-15
AU2009262198A1 (en) 2009-12-30
MX2010014568A (es) 2011-03-29
UA101057C2 (en) 2013-02-25
WO2009158431A2 (en) 2009-12-30
BRPI0914545A2 (pt) 2017-05-23
CN102203083A (zh) 2011-09-28
AU2009262198B2 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
EA201100077A1 (ru) Производные пиримидина в качестве ингибиторов киназы
EA201100078A1 (ru) Производные пиримидина в качестве ингибиторов киназы
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
EA201001597A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200970557A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
EA201001596A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA201100687A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
MX2012013197A (es) Inhibidores de indazol de cinasa.
NZ711376A (en) Heteroaryl compounds and uses thereof
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200970156A1 (ru) Пиридизиноновые производные
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MX2009003793A (es) Inhibidores de cinasa.
TN2010000602A1 (en) Pyrimidine derivatives as kinase inhibitors
CU20100259A7 (es) Derivados de pirimidina como inhibidores de quinasa